A Phase Ib Study of Sapacitabine and Olaparib in Patients with <i>BRCA1/2-</i> Mutated Metastatic Breast Cancer
Sapacitabine with olaparib produces high rates of hematologic toxicity. However, the ORR of 50%, mPFS of 9.7 months, and durability of response in some patients suggest possible combinatorial benefit. Further exploration of olaparib with different sapacitabine schedules or substitution of a PARP1-selective inhibitor to potentially decrease hematologic toxicity is warranted.
Authors
- Raechel Davis
- Filipa C. Lynce (ORCID: https://orcid.org/0000-0001-6615-7076)
- Judy Ellen Garber (ORCID: https://orcid.org/0000-0001-9449-3982)
- Huy Nguyen (ORCID: https://orcid.org/0000-0002-4424-1047)
- Philip D. Poorvu (ORCID: https://orcid.org/0000-0003-3664-5727)
- Kavita Garg (ORCID: https://orcid.org/0009-0009-7361-4699)
- Molly K. DiLullo (ORCID: https://orcid.org/0009-0005-1036-796X)
- Brittany Bychkovsky (ORCID: https://orcid.org/0000-0001-7969-0603)
- Alan D. D’Andrea (ORCID: https://orcid.org/0000-0001-6168-6294)
- Geoffrey Ira Shapiro (ORCID: https://orcid.org/0000-0002-3331-4095)
- Cloud Peter Paweletz (ORCID: https://orcid.org/0000-0002-2287-5663)
- Nabihah Tayob (ORCID: https://orcid.org/0000-0001-6088-167X)
- Lee P. Lim
- Sara M. Tolaney (ORCID: https://orcid.org/0000-0002-5940-8671)
- Victoria Attaya (ORCID: https://orcid.org/0009-0004-3440-0501)
- Bose Kochupurakkal (ORCID: https://orcid.org/0000-0001-8929-3070)
- Noah Graham (ORCID: https://orcid.org/0009-0009-0622-683X)
- Mark Li (ORCID: https://orcid.org/0009-0006-4105-8876)
Institutions
- Broad Institute (US)
- Harvard University (US)
- Exact Sciences (United States) (US)
- Dana-Farber Cancer Institute (US)
- Dana-Farber/Harvard Cancer Center (US)
- Dana-Farber Brigham Cancer Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-0571
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00